Short thread on $TEVA development for key drug AJOVY:

Ajovy, which is a drug already marketed in the US and EU, is used to treat patients with at least four migraine days in a month

$TEVA has reported additional data for its migraine drug, Ajovy, which contains the active ingredient Fremanezumab. Positive results were presented at the Migraine Trust International Symposium (MTIS) in UK, and later confirmed in a company press release

In two phase III trials, titled Halo and Focus, Ajovy in both quarterly and monthly dosing demonstrated efficacy, reducing migraine attacks by over 50% compared to a placebo in people with migraine in addition to one or more psychiatric conditions

Sub-analysis of Focus also tested people diagnosed with depression who had previously received 2 to 4 inadequate preventive migraine treatments and observed reductions in monthly migraine days and monthly headache days with quarterly and monthly Fremanezumab vs placebo $TEVA